The writer argues tirzepatide does more than curb eating, pointing to its effects on appetite, fullness and blood sugar. A general explainer.
Recap by typeshit. Post by Facebook on Facebook.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
One product appeared to come from a 'research use only' vendor called AlphaLabs. Harvard's Pieter Cohen urges the FDA to investigate; Public Citizen counts at least 14 hospitalizations.
Buchanan Ingersoll & Rooney outlines what compounding pharmacies should watch for now that the FDA has sent its interim peptide policy to the White House for review.
Loading…